These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19408831)

  • 1. Low-molecular weight heparin enoxaparin in the treatment of acute coronary syndromes without ST segment elevation.
    Mitrovska S; Jovanova S
    Bratisl Lek Listy; 2009; 110(1):45-8. PubMed ID: 19408831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
    J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of anticoagulation in acute coronary syndromes.
    Latour-Pérez J; de-Miguel-Balsa E
    Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
    Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Costs of Enoxaparin Monotherapy Versus Unfractionated Heparin Monotherapy in Treating Acute Coronary Syndrome.
    Rosenthal N; Xiao Z; Kartashov A; Levorsen A; Shah BR
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):93-101. PubMed ID: 32578166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
    Petersen JL; Mahaffey KW; Hasselblad V; Antman EM; Cohen M; Goodman SG; Langer A; Blazing MA; Le-Moigne-Amrani A; de Lemos JA; Nessel CC; Harrington RA; Ferguson JJ; Braunwald E; Califf RM
    JAMA; 2004 Jul; 292(1):89-96. PubMed ID: 15238596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of enoxaparin and dalteparin with unfractionated heparin in the treatment of non-ST elevated acute coronary syndrome.
    Ahmed M; Tariq M; Noor L; Din SU; Hafizullah M
    J Ayub Med Coll Abbottabad; 2011; 23(3):60-3. PubMed ID: 23272437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
    Puymirat E; Schiele F; Ennezat PV; Coste P; Collet JP; Bonnefoy-Cudraz E; Roul G; Richard P; Simon T; Danchin N
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):211-9. PubMed ID: 25075006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.